BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma

Abstract

Background Malignant peritoneal mesothelioma (PeM) is a rare and fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or chemotherapy, and no effective targeted therapies for PeM exist. Some immune checkpoint inhibitor studies of mesothelioma have found positivity to be associated with a worse prognosis. Methods To search for novel therapeutic targets for PeM, we performed a comprehensive integrative multi-omics analysis of the genome, transcriptome, and proteome of 19 treatment-naïve PeM, and in particular, we examined BAP1 mutation and copy number status and its relationship to immune checkpoint inhibitor activation. Results We found that PeM could be divided into tumors with an inflammatory tumor microenvironment and those without and that this distinction correlated with haploinsufficiency of BAP1 . To further investigate the role of BAP1 , we used our recently developed cancer driver gene prioritization algorithm, HIT’nDRIVE, and observed that PeM with BAP1 haploinsufficiency form a distinct molecular subtype characterized by distinct gene expression patterns of chromatin remodeling, DNA repair pathways, and immune checkpoint receptor activation. We demonstrate that this subtype is correlated with an inflammatory tumor microenvironment and thus is a candidate for immune checkpoint blockade therapies. Conclusions Our findings reveal BAP1 to be a potential, easily trackable prognostic and predictive biomarker for PeM immunotherapy that refines PeM disease classification. BAP1 stratification may improve drug response rates in ongoing phases I and II clinical trials exploring the use of immune checkpoint blockade therapies in PeM in which BAP1 status is not considered. This integrated molecular characterization provides a comprehensive foundation for improved management of a subset of PeM patients. Electronic supplementary material The online version of this article (10.1186/s13073-019-0620-3) contains supplementary material, which is available to authorized users.

Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice

“…Inflammation is closely associated with human MM and is ascribed to a response inflicted by exposure to asbestos fibers (Robinson and Lake, 2005; Shrestha et al, 2019). Interestingly, our BNC mesothelioma model, which is exclusively based on engineered tumor suppressor gene deletions, closely mimics this inflammatory phenotype.…”

Multiomics Characterization of Potential Therapeutic Vulnerabilities in Low-grade Serous Ovarian Carcinoma

“…Thus, efficient analytical tools and large datasets are needed to reduce false discovery rates and improve prediction accuracy. HIT'nDRIVE analysis exploits the power of analyzing multiomics data and can also be used to enhance discovery in rare cancers [66]. Using…”

Well-Differentiated Papillary Mesothelioma of the Peritoneum is Genetically Distinct from Malignant Mesothelioma

“…Our study confirms lack of copy-number alterations in BAP1, SETD2, PBRM1, SMARCC1, CDKN2A/B, LATS1/2, and NF2. Copy-number loss of BAP1, SETD2, PBRM1, and SMARCC1 is often observed in peritoneal mesothelioma 6,30 . Copy-number loss of BAP1, CDKN2A/B, LAST1/2, and NF2 is frequently found in pleural mesothelioma 4,5 .…”

“…We utilized DNA sequencing datasets of two publicly available patient cohorts of peritoneal mesothelioma -VPC cohort 6 and AACR Project GENIE Cohort 20 . We used mutation and copy number profiles from both datasets for comparison with the genomic profiles of WDPM cases.…”

“…For this, we leveraged the DNA sequencing data from two recently published peritoneal mesothelioma patient cohorts 6,20 . We first assessed the pattern of mutations in WDPM and peritoneal mesothelioma cases.…”